Search results
Results from the WOW.Com Content Network
Disseminated intravascular coagulation (DIC) is a condition in which blood clots form throughout the body, blocking small blood vessels. [1] Symptoms may include chest pain, shortness of breath, leg pain, problems speaking, or problems moving parts of the body. [1] As clotting factors and platelets are used up, bleeding may occur. [1]
Disseminated intravascular coagulation or DIC is caused by a systemic response to a specific condition including sepsis and severe infection, malignancy, obstetric complications, massive tissue injury, or systemic diseases. Disseminated intravascular coagulation is an activation of the coagulation cascade which is usually a result of an ...
English: What is disseminated intravascular coagulation (DIC)? DIC's a condition where the body has both widespread clotting, leading to organ ischemia, while at the same time has a depletion of clotting factors, leading to bleeding. Sources: Aster, J.C., & Bunn, H. F. (2017). Pathophysiology of Blood Disorders (2nd ed.).
Disseminated intravascular coagulation (DIC) involves widespread microthrombi formation throughout the majority of the blood vessels. This is due to excessive consumption of coagulation factors and subsequent activation of fibrinolysis using all of the body's available platelets and clotting factors. The result is hemorrhaging and ischemic ...
Initial treatment for any type of transfusion reaction, including AHTR, is discontinuation of the transfusion. Fluid replacement and close monitoring of vital signs are important. People with AHTR are managed with supportive care , which may include diuretics , blood pressure support, and treatment of disseminated intravascular coagulation ...
It is characterized by overwhelming bacterial infection meningococcemia leading to massive blood invasion, organ failure, coma, low blood pressure and shock, disseminated intravascular coagulation (DIC) with widespread purpura, rapidly developing adrenocortical insufficiency and death.
Monoclonal antibodies like eculizumab and caplacizumab can assist with atypical hemolytic uremic syndrome and acquired thrombotic thrombocytopenic purpura respectively whilst dexamethasone can help with immune thrombotic thrombocytopenic purpura and low molecular weight heparin can help with disseminated intravascular coagulation. [citation needed]
Purpura fulminans with disseminated intravascular coagulation should be urgently treated with fresh frozen plasma (10–20 mL/kg every 8–12 hours) and/or protein C concentrate to replace pro-coagulant and anticoagulant plasma proteins that have been depleted by the disseminated intravascular coagulation process. [2] [3] [4] [7]